Arylalkylamine compound and process for preparing the same
The present invention relates to an arylalkylamine compound represented by the following formula [I] or a pharmaceutically acceptable salt thereof, a process for preparing the same, and use of the above-mentioned compound as an activating compound (CaSR agonist) of a Ca sensing receptor, a pharmaceutical composition containing the above-mentioned compound as an effective ingredient, etc. The symbols in the formula represent the following meanings: Ar: optionally substituted aryl or optionally substituted heteroaryl here, the cyclic portion of the heteroaryl is bicyclic heterocyclic ring in which 5- to 6-membered monocyclic heterocyclic ring containing 1 or 2 hetero atom(s) and benzene ring are fused; R 1 : a group selected from the group consisting of optionally substituted cyclic hydrocarbon group, and optionally substituted heterocyclic group; n: an integer of 1 to 3; X: single bonding arm, —CH 2 —, —CO—, —(CH 2 ) m —CO—, —CH(R 2 )—CO—, —(CH 2 ) p —Y—(C(R 3 )(R 4 )) q —CO—, —NH—CO— or —N(R 5 )—CO—; in the above-mentioned respective definitions of the X, the bonding arm described at the left end represents a bond with R 1 ; m is an integer of 1 to 3; p is an integer of 0 to 2; q is an integer of 0 to 2; Y: —O— or —SO 2 —; R 2 : phenyl or lower alkyl; R 3 , R 4 : each independently represents hydrogen atom or lower alkyl; R 5 : lower alkyl; provided that the ring portion of the group represented by R 1 is neither naphthylidine nor partially saturated group thereof, and, when X is —CH 2 — or —CO—, R 1 is not naphthyl.
1. An arylalkylamine compound represented by the formula [I-e]:
the symbols in the formula represent the following meanings:
Ar: represents naphthyl optionally substituted by one or more groups selected from the group consisting of halogen, hydroxy, cyano, halo-lower alkyl, lower alkyl, lower alkoxy and lower alkylthio;
R 1 : represents a phenyl group optionally substituted by one or more substituents selected from the group consisting of:
halogen,
cyano,
nitro
oxo group,
hydroxy,
carboxy,
lower alkyl optionally substituted by one or more groups selected from the group consisting of halogen, cyano, nitro, oxo, carboxy, hydroxy, lower alkoxy and halo-lower alkoxy,
lower alkoxy optionally substituted by one or more groups selected from the group consisting of halogen, cyano, nitro, oxo, carboxy and hydroxyl,
amino optionally mono- or di-substituted by a group selected from the group consisting of lower alkyl and halo-lower alkyl,
5 to 6-membered monocyclic heterocyclic group selected from the group consisting of tetrazole, pyridazinyl, and partially saturated cyclic group thereof, which is optionally substituted by one or more groups selected from the group consisting of halogen, cyano, nitro, oxo, carboxy, hydroxy, lower alkyl, halo-lower alkyl, lower alkoxy, halo-lower alkoxy, and acyl,
phenyl optionally substituted by one or more groups selected from the group consisting of halogen, cyano, nitro, oxo, carboxy, hydroxy, lower alkyl, halo-lower alkyl, lower alkoxy, halo-lower alkoxy, and acyl, and
acyl;
n: is an integer of 2;
X: represents single bonding arm;
in the above-mentioned respective definitions of the X, the bonding arm described at the left end represents a bond with R 1 ;
or a pharmaceutically acceptable salt thereof.
2. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein Ar is naphthyl which is optionally substituted by one or more groups selected from the group consisting of lower alkyl and lower alkoxy.
3. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein when R 1 is optionally substituted phenyl, the one or more substituents is selected from the group consisting of
halogen,
carboxy,
lower alkyl optionally substituted by one or more groups selected from the group consisting of halogen, cyano, nitro, oxo, carboxy, hydroxy, lower alkoxy and halo-lower alkoxy,
lower alkoxy optionally substituted by one or more groups selected from the group consisting of halogen, cyano, nitro, oxo, carboxy and hydroxyl,
5 to 6-membered monocyclic heterocyclic group selected from the group consisting of tetrazole, pyridazinyl, and partially saturated cyclic group thereof, which is optionally substituted by one or more groups selected from the group consisting of halogen, cyano, nitro, oxo, carboxy, hydroxy, lower alkyl, halo-lower alkyl, lower alkoxy, halo-lower alkoxy, and acyl, and
acyl.
4. A pharmaceutical composition comprising:
an arylalkylamine compound represented by the formula [I-e]:
the symbols in the formula represent the following meanings:
Ar: represents naphthyl optionally substituted by one or more groups selected from the group consisting of halogen, hydroxy, cyano, halo-lower alkyl, lower alkyl, lower alkoxy and lower alkylthio;
R 1 : represents a phenyl group optionally substituted by one or more substituents selected from the group consisting of:
halogen,
cyano,
nitro
oxo group,
hydroxy,
carboxy,
lower alkyl optionally substituted by 1 or plural groups selected from the group consisting of halogen, cyano, nitro, oxo, carboxy, hydroxy, lower alkoxy and halo-lower alkoxy,
lower alkoxy optionally substituted by 1 or plural groups selected from the group consisting of halogen, cyano, nitro, oxo, carboxy and hydroxyl,
amino optionally mono- or di-substituted by a group selected from the group consisting of lower alkyl and halo-lower alkyl,
5 to 6-membered monocyclic heterocyclic group selected from the group consisting of tetrazole, pyridazinyl, and partially saturated cyclic group thereof, which is optionally substituted by 1 or plural groups selected from the group consisting of halogen, cyano, nitro, oxo, carboxy, hydroxy, lower alkyl, halo-lower alkyl, lower alkoxy, halo-lower alkoxy, and acyl,
phenyl optionally substituted by 1 or plural groups selected from the group consisting of halogen, cyano, nitro, oxo, carboxy, hydroxy, lower alkyl, halo-lower alkyl, lower alkoxy, halo-lower alkoxy, and acyl, and
acyl;
n: is an integer of 2;
X: represents single bonding arm;
or a pharmaceutically acceptable salt thereof as an effective ingredient; and
a pharmaceutically acceptable carrier.
5. The pharmaceutical composition according to claim 4 , wherein it is for treatment of hyperparathyroidism.
6. The pharmaceutical composition according to claim 5 , wherein the hyperparathyroidism is primary hyperparathyroidism, secondary hyperparathyroidism, or ectopic hyperparathyroidism.
7. The compound according to claim 1 , which is
or a pharmaceutically acceptable salt thereof.
8. A pharmaceutical composition, comprising:
an effective amount of the compound of claim 7 or a pharmaceutically acceptable salt thereof; and
a pharmaceutically acceptable carrier.
9. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein Ar is unsubstituted naphthyl.
10. The compound according to claim 1 , which is
or a pharmaceutically acceptable salt thereof.
11. The compound according to claim 1 , which is
or a pharmaceutically acceptable salt thereof.